(Total Views: 364)
Posted On: 06/08/2025 5:08:44 PM
Post# of 154605
*PARP helps repair DNA when it becomes damaged. DNA damage may be caused by many things, including exposure to UV light, radiation, certain anticancer drugs, or other substances in the environment. In cancer treatment, blocking PARP may help keep cancer cells from repairing their damaged DNA, causing them to die.
*PARP treatments are approved in ovarian, primary peritoneum, fallopian tube, breast, pancreatic, and prostate cancers that have BRCA1/2 pathogenic variants
*LYNPARZA continues to be the most widely prescribed medication in the PARP inhibitor family for four tumor types. It is being used for conditions like breast, ovarian, and prostate cancer.
*Lynparza generated approximately $2.7 billion in revenue globally, with about 40% coming from the United States due to growth in usage in breast, ovarian, and prostate cancers.
The global PARP Inhibitors Market was valued at approximately USD 7.9 billion in 2023 and is projected to reach USD 8.4 billion in 2024. By 2033, the market is expected to reach about USD 23.5 billion, with another projection estimating USD 16.15 billion by 2034. The market is anticipated to grow at a CAGR of roughly 12.1% from 2024 to 2033.
The market is competitive, featuring companies like AstraZeneca, Merck & Co., GlaxoSmithKline plc, Pfizer Inc., and Johnson & Johnson.
*PARP treatments are approved in ovarian, primary peritoneum, fallopian tube, breast, pancreatic, and prostate cancers that have BRCA1/2 pathogenic variants
*LYNPARZA continues to be the most widely prescribed medication in the PARP inhibitor family for four tumor types. It is being used for conditions like breast, ovarian, and prostate cancer.
*Lynparza generated approximately $2.7 billion in revenue globally, with about 40% coming from the United States due to growth in usage in breast, ovarian, and prostate cancers.
The global PARP Inhibitors Market was valued at approximately USD 7.9 billion in 2023 and is projected to reach USD 8.4 billion in 2024. By 2033, the market is expected to reach about USD 23.5 billion, with another projection estimating USD 16.15 billion by 2034. The market is anticipated to grow at a CAGR of roughly 12.1% from 2024 to 2033.
The market is competitive, featuring companies like AstraZeneca, Merck & Co., GlaxoSmithKline plc, Pfizer Inc., and Johnson & Johnson.
(4)
(0)
